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INTRODUCTION 
Acquired Immuno Deficiency Syndrome (AIDS) was first 
recognized in 1981, manifested by the opportunistic infections and 
malignancy (pneumocystis carinii pneumonia, kaposi’s sarcoma) in 
homosexual men. In 1983, French scientist   Prof. Luc Montagnier and 
his co –workers isolated the causative viral agent, which was later named 
as Human Immunodeficiency Virus.1  In 1985, a sensitive enzymes linked 
immunosorbant assay (ELISA) was developed.  
In 1986, Montagnier’s group discovered a new type of HIV in 
West Africa and labeled it as  HIV-2.2  The origin of the virus is unclear. 
The most likely scenario is that the HIV was introduced into human from 
another primate in  Sub –Saharan Africa.3   
WHO and UNAIDS estimate that at the end of 2001, 40 million 
people around the world were living with HIV.4  India is now considered 
the country with the largest number of infected persons in the world.5 
India alone accounts for 4 million cases. The spread mainly occurs 
through heterosexual route.  
 The HIV epidemic is generalized in 6 Indian states-Maharashtra, 
Tamil Nadu, Karnataka, Andhra Pradesh, Manipur and Nagaland.  In 
Tamil Nadu, almost 5 lakh people are infected with HIV and the infection 
rate is 3 times higher in the villages than in the cities. 
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ETIOLOGY: 
 Human Immuno Deficiency Virus (HIV) is a lymphotrophic 
human retro virus. It is a RNA virus with icosahedral structure. The 
hallmark of the virus is the reverse transcription of the genome RNA to 
DNA inside the host cell by the enzyme reverse transcriptase. 
INCUBATION PERIOD: 
 Incubation period of Acute Primary HIV infection (Acute Sero- 
conversion Syndrome) is within 3-4 weeks. Average period to develop 
AIDS is 8-10 years. The documented cytopathic effect is 50- 80 
cells/microlitre per years. 
PROBABILITY OF HIV-1 INFECTION PER EXPOSURE 
 MODE OF INFECTION INFECTION PER EXPOSUR
Male to female ,unprotected  vaginal sex            0.1% to 0.2% 
Female to Male, unprotected vaginal sex            0.03% to 0.1% 
Male to Male, unprotected anal sex            0.5 to  3% 
Needle stick            0.3% 
Mother to child transmission           13 to  48% 
Exposure to contaminated blood products            90 to 100 % 
 
MOLECULAR EPIDEMIOLOGY OF HIV: 
 The diversity of the global AIDS pandemic is also reflected in the 
heterogenecity of the viral subtypes or clades of HIV.   According to  
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DNA sequence data, HIV-1 can be divided into three major groups. 
Group M (major) which contains ten genetically distinct subtypes- A to J 
Group O (outlier) which contains several heterogeneous virus.  Group N 
(Cameroontype). 
In addition there are at least 5 subtypes of HIV –2, the predominant 
virus in West Africa. Importance of molecular epidemiology is that it can 
offer clues as to how the virus spreads between the region and countries. 
Subtype C virus (of the M group) is prevalent in India. In Asia, HIV-1 
isolates of subtypes E, C and B predominate.  
 About 5% of the infected persons progress to AIDS within 2 to 3 
years and are called Rapid Progressors.  About 5% of the infected persons 
do not progress to AIDS even after 10 years and are called Long Term 
Non Progressors. The reasons are being, mutant nef gene of HIV6 and 
defective CCR-5 co-binding protein on the macrophage due to genetic 
abnormality in the patient.7 
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WHO Staging system for HIV infection 
 
Clinical stage I Clinical stage II Clinical stage III Clinical stage IV 
1. Asymptomatic 
HIV infection 
 
2. Persistent  
Generalized  
Lymphadeno- 
pathy 
 
3.Primary HIV 
infection 
 
Performance- 
scale 1:  
Asymptomatic, 
Normal activity 
 
1.Weight loss 
<10% of body 
weight 
 
2. Minormuco- 
Cutaneous 
manifestations 
(seb.derm, 
fungalnail- 
infections,   
recurrent oral 
ulcers , angular 
chelitis ) 
 
3.Herpes zoster 
with in the past 5 
years 
 
4.Recurrent Upper 
Respiratory 
Infections 
(Bacterial sinusitis) 
 
And / or 
Performance-  
scale 2: 
symptomatic, 
Normal activity 
 
1.Weight loss>10 % 
of body weight 
 
2.Un explained 
Chronic diarrhoea 
> 1 month 
 
3.Un explained 
prolonged fever 
(intermittent or 
constant )  
> 1 month 
 
4.Oral Candidiasis 
 
5.Oral hairy 
leckoplakia 
 
6.Pulmonary 
tuberculosis 
 
7. Severe 
Bacterial 
infections 
(pneumonia, 
pyomyositis) 
 
8. Cervical intra 
epithelial 
neoplasia 
And / or  
performance - 
scale 3 :  
Bed-ridden, 
< 50 % of the  
day  during  
past month 
Candidiasis of the 
bronchi, trachea or 
lungs, Oesophageal  
candidiasis, Cervical 
cancer,  
Coccidioidomycosis, 
Cryptococcosis – 
(extra pulmonary), 
Cryptospori diosis – 
chronic intestinal (> 1 
month duration), 
Isosporiasis – chronic 
intestinal (> 1 month 
duration), 
Cytomegalovirus 
disease (other than 
lung, spleen and 
nodes),  CMV retinitis 
(with loss of vision), 
HIV encephalopathy,   
Herpes simplex-
(chronic ulcer, 
bronchitis, pneumonia 
or Oesophagitis),   
Histoplasmosis – 
(disseminated  or extra  
pulmonary),     
Kaposi’s  sarcoma,    
Lymphoma,     MAC, 
M. kansasi infection – 
(pulmonary), 
disseminated,      
M.tuberculosis –extra 
pulmonary , 
disseminated  
Pneumocystis carinii 
pneumonia, 
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Recurrent pneumonia,      
Progressive multi focal 
leuko encephalopathy,      
Salmonella septicemia – 
recurrent,       
Toxoplasmosis,      
Wasting syndrome 
And / or Performance - 
scale 4 : Bed-ridden   
> 50 % of the day   
during past month 
  
Hepato – biliary abnormalities        
In advanced HIV infected patients, with CD4 < 200 , Hepato – 
biliary abnormalities  were noted, even though they are asymptomatic. In 
literature, it was stated that, such abnormalities were due to the CMV, 
Cryptospora , etc and   no specific drugs were available and hence the 
role of ART was mentioned in such conditions8. Hence the present study 
was under taken, also to find out the response to ART, since ART centre 
was launched recently in our set-up. 
         In HIV infected patients, Liver diseases can be classified into         
four Groups : 
1. Those that are associated with HIV related immune compromise 
and are rarely encountered in non immuno suppressed 
individuals [eg. AIDS cholangiopathy , Mycobacterium avium 
intracellurare (MAC) and Cyto Megalo virus (CMV) hepatitis ] 
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2.  Those that occur in both immuno compromised and immuno-
competent individuals, but that are more prevalent in those who 
are HIV positive than those who are HIV negative   [ eg. HBV 
and HCV infection] 
3. Drug- induced hepatotoxicity, which results from the multiple 
HIV specific ARV drugs and other antimicrobials. 
4. All the common hepato-biliary diseases that afflict those who 
are HIV negatives [eg . gallstones – associated cholecystitis and 
alcoholic liver disease ] 
 
The advent of Anti retroviral therapy (ART/ARV) has 
revolutionized the management of HIV infection. From an incurable 
disease, highly active anti retroviral therapy has made HIV infection a 
treatable and chronically manageable illness. 
       In 1987, Zidovudine was reported to be useful in managing the 
patients with HIV infection for the first time.9  The failure of monotherapy 
led to a focus on combination treatment with two nucleoside analogues.  
The failure of long lasting clinical benefits with dual nucleoside 
analogue therapy and the development of protease inhibitors led to triple 
therapy with one protease inhibitor and two nucleoside analogues.  
HAART combination consist of one protease inhibitor with two 
NRTIs  or   one NNRTI with two NRTIs. 
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         In our ART centre, two NNRTIs (Nevirapine&Efavirenz), and three 
NRTIs (Zidovudine, Stavudine & Lamivudine ) are available.  We are 
using ART regimen including one NNRTI with two NRTIs.  
 
WHO Recommendations for ART in adults with HIV infection 
 
1. WHO stage IV irrespective of CD4 (Cluster of Differentiation) cell 
count.  
2. WHO stage III with CD4 cell count <350 cells/ mm3. 
3. WHO stage I & II with CD4 cell count <200 cells/ mm3. 
 
Side effects of ARV Drugs  
The use of highly active antiretroviral therapy (HAART) against 
HIV has become the standard of care.  Hepatotoxicity has been noted 
with all of the protease inhibitors as well as many of the nucleoside and 
nonnucleoside analog drugs.  A recent study compared the incidence of 
hepatotoxicity in patients receiving several different regimens with and 
without protease inhibitors and found that ritonavir was associated with a 
higher incidence of hepatotoxicity when compared with indinavir, 
nelfinavir, saquinavir, and nucleoside analog regimens. 
 Hepatic steatosis is another pattern of injury noted as a 
complication of HIV medications.  Hepatic steatosis in the setting of 
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lactic acidosis has been described for zidovudine, didanosine, and now 
stavudine.   
Nucleouside Reverse Transcriptase Inhibitors (NRTIs) are 
commonly associated with Hepatic steatosis.  Non Nucleouside Reverse- 
Transcriptase Inhibitors (NNRTIs)  usually cause Hepatitis.  Protease -
Inhibitors (PIS) are associated with Liver toxicity in the form of  jaundice 
(hyperbilirubinemia and elevated  liver enzymes ) 
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AIMS  &  OBJECTIVES 
 
 
 
 
1. To find out the hepato- biliary abnormalities in HIV positive 
patients. 
 
2. To correlate hepato- biliary abnormalities with their CD4 counts. 
 
3. To find out Hepatitis B and Hepatitis C co-infection in HIV 
patients. 
 
4. To find out the response of the hepato- biliary abnormalities to 
Anti Retro Viral Therapy. 
 
5. To detect Anti Retro Viral Therapy induced hepato- biliary 
abnormalities 
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REVIEW OF LITERATURE 
 
 
Classification of Hepato-biliary abnormalities in HIV infection10 : 
 
1. Hepatic disorders are caused by 
 
a)  Viral hepatitis  
         Hepatits B (HBV) 
         Hepatits C (HCV) 
b)  Opportunistic infections : (OI) 
 
1. Mycobacterium avium intracellulare (MAC) 
2. Mycobacterium tuberculosis (Myc. TB) 
3. Cytomegalo virus (CMV) ( associated with biliary tract 
disease) 
4. Herpes simplex virus 
5. Ebstein Barr Virus (EBV) 
6. Cryptococcus Neoformans  ( associated with biliary tract 
disease) 
7. Histoplasmosis 
8. Candida albicans ( associated with biliary tract disease) 
9. Cocidomycosis 
10. Microspordia ( associated with biliary tract disease) 
11. Toxoplasmosis 
12. Bacillary peliosis 
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c) Tumors  
 
Hodgkin’s & Non Hodgkin’s Lymphoma 
                Kaposi’s sarcoma 
 
     d) Hepato toxic  drugs :  
 
sulphonamides  
ARV drugs : Nevirapine, Zidovudine etc 
Antibiotics 
INH 
Anti fungals 
Tranquillizers 
 
       Biliary disorders 
 
            AIDS Cholangiopathy 
            Lymphoma 
          Kaposi’s sarcoma 
            Acalculus cholecystitis 
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Hepatic Disease in HIV based on CD4 Lymphocyte count11 
 
CD4 
Lymphocyte 
count 
 
Predominantly Cholestatic Predominantly Hepatocellular 
500 or less Drug toxicity 
Mycobacterium tuberculosis         
Kaposi’s sarcoma          
Lymphoma 
Cholelithiasis 
Acalculus cholecystitis 
Bacterial abscess 
Drug toxicity 
Steatosis 
 
Viral Hepatitis 
Herpes simplex 
250 or less Fungal infection 
Candidiasis 
Histoplasmosis 
Cryptococcosis 
Blastomycosis 
Cryptosporidium 
AIDS Cholangiopathy 
Bartonella/bacillary angiomatosis and 
peliosis 
 
 
 
Pneumocystis 
carinii 
100 or less Cytomegalovirus 
Mycobacterium avium intracellulare  
Microspordia 
 
Cytomegalovirus 
 
 
          
Hepatitis B Virus infection :  
Risk factors for acquisition of HBV infection are similar to those 
for acquisition of HIV infection. Both viruses have an increased 
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prevalence in persons with multiple sexual partners and in injection drug 
users.12  Markers of prior or active HBV infection are present in more 
than 80% of patients with HIV infection, approximately 10% of whom 
are HBsAg positive, as described by Hollander et al.13.  After acute 
infection with HBV, patients with HIV infection are at greater risk of 
developing chronic HBV infection than are those without HIV infection.  
Compared with patients with HBV infection alone, HBV/HIV 
coinfected patients have higher levels of viral replication, lower serum 
ALT values, and milder histologic disease. Historically, HBV infection 
has not adversely affected survival in HIV-positive patients,13  although 
with improving survival of HIV-infected patients, liver disease is 
emerging as an important clinical problem.  
Coinfected patients have reduced rates of response to alpha-
interferon. Data suggest that there is limited benefit of interferon alone in 
the setting of HIV. However, there are good response rate to lamivudine 
in co infected patients. Therefore, patients with evidence of actively 
replicating virus and liver disease should be considered for treatment.  
Lamivudine administered at 100 mg/day is sufficient to control 
HBV, but HIV patients are often on higher doses given that lamivudine is 
also used as treatment for HIV at a dose of 300 mg/ day14. Unfortunately, 
mutation of HBV virus and subsequent resistance to lamivudine is 
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common. Currently, there are no additional drugs approved for the 
treatment of lamivudine resistant HBV. In HIV positive patients without 
serologic evidence of past or present HBV infection, vaccination is 
largely ineffective.                                                                                                           
Hepatitis C Virus infection :  
Coinfection with HCV and HIV is common, because of shared 
transmission routes.  Berenguer and wright et al., observed that rates of 
HCV seropositivity ranging from 4% to 100% in their study, depending 
on the transmission category, with higher rates among injection drug 
users and recipients of blood transfusions than among men who have sex 
with men and heterosexual contacts.15 
The clinical course of HCV infection in HIV patients is often more 
aggressive. Multiple studies have demonstrated an increased rate of 
fibrosis and prevalence of cirrhosis. chronic hepatitis C is a growing 
cause of morbidity and mortality in patients who are HIV positive. 
Indeed, several studies have shown that HIV/HCV–co infected patients 
have more severe liver injury and a worse prognosis than do patients   
with HCV infection alone.15  
The reasons why hepatic decompensation develops more rapidly in 
coinfected patients than in those with HCV infection alone are unknown. 
Several hypotheses have been raised:  
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1) HIV does not seem to be cytopathic to hepatocytes, but it can be 
demonstrated in Kupffer cells in patients with AIDS and could have 
pathologic effects on the liver by stimulating abnormal production of 
fibrogenic cytokines;16  
2) hepatic decompensation could be precipitated by AIDS-related 
opportunistic infections in patients who have already developed cirrhosis 
as a result of chronic HCV infection;  
3) HIV immunosuppression enhances serum HCV RNA levels, 
which have been shown in some studies to be associated with more 
severe liver damage; and  
4) Distribution of HCV genotypes and HCV diversity may be 
different in coinfected patients compared with those infected with HCV 
alone.  
Additional specific features of HCV infection have been proposed 
to occur more frequently in coinfected patients as compared with patients 
infected with HCV alone. These include 1) lack of sensitivity of serologic 
assays in diagnosing HCV infection, 2) enhancement of HCV replication, 
and 3) higher risk of heterosexual and perinatal transmission of HCV 
infection. Data to support some of these observations are stronger than 
others. Interferon therapy may be tried, but will have the greatest benefit , 
only in those with higher CD4 counts with the modern therapy of HIV,     
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the number of doubly infected persons with good immune function will 
increase and combined ribavarin / interferon therapy can be tried17.                                      
Mycobacterium avium intracellulare :  
Typically, this is a late-stage infection, and the liver involvement is 
part of systemic infection. The pathologic hallmark is the presence of 
poorly formed granulomas associated with large numbers of acid-fast 
bacilli within foamy histiocytes18. Acid-fast smear of infected tissue 
usually reveals organisms, although distinction from Mycobacterium 
tuberculosis is not possible by smear alone. Patients typically have 
systemic systems, including fever, lymphadenopathy, diarrhea, and night 
sweats. Associated bone marrow infiltration is common.  
The diagnosis can often be established by blood culture, bone- 
marrow, or lymphnode examination prior to consideration of liver 
biopsy.19 Imaging studies may reveal diffuse intra abdominal adenopathy. 
Liver abnormalities typically include disproportionate elevation of serum 
alkaline phosphatase,with modest elevation of bilirubin, AST and ALT, 
less frequently, hepatomegaly. The mean survival is only 69 days.   
Mycobacterium tuberculosis :    
Mycobacterium tuberculosis can occur at an earlier stage, and is 
more prevalent in injection drug users than in other categories. 
Granulomas are found in Liver biopsy specimen in about 25% of persons 
with pulmonary TB and 80% of those with extrapulmonary TB.  Multiple 
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granulomas may also be seen in persons with impaired immune response. 
Reynolds et al., described about granulomatous hepatitis in AIDS 
patients20  When the CD4>200, infection is pulmonary, where as atypical 
presentations, including hepatic involvement are seen in patients with 
severe immuno-deficiency.  
Extra pulmonary tuberculosis, including liver disease, is more 
common in HIV infected patients, and may be manifested by abdominal 
pain, jaundice, or hepato splenomegaly21. Treatment of M.tuberculosis in 
HIV patients is same like others. But in our RNTCP program, we are 
giving either Category I or Category II22. Category III is not given for 
HIV patients. Rifamycins may induce CYP450; therefore, drug-drug 
interactions can be expected with HAART (PI and NNRTI)23.      
Cytomegalo virus infection:  
Cytomegalo virus infection is late and part of generalized disease. 
It is associated with fever and weight loss. Diagnosis is made by 
demonstrating nuclear and cytoplasmic inclusions in Kupffer cells, bile 
duct epithelium and occasionally hepatocytes24. Mono nuclear cell- 
infiltration or neutrophils may be present.Non specific elevations of  
transaminases are noted. It also causes granulamatous hepatitis and 
Acalculous cholecystitis.  
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BACILLARY ANGIOMATOSIS  
 
Bacillary Angiomatosis is an infectious disorder that primarily 
affects persons with AIDS or other immunodeficiency states. The 
causative agents have been identified as the gram-negative bacilli 
Bartonella henselae, which is difficult to cultivate and, in some cases, 
B.quintana.25 Infection is frequently associated with exposure to cats. 
Bacillary angiomatosis is characterized most commonly by 
multiple blood-red papular skin lesions, but disseminated infection with 
or without skin involvement has also been described.26 The causative 
bacilli can infect liver, lymph nodes, pleura, bronchi, bones, brain, bone 
marrow, and spleen. Additional manifestations include persistent fever, 
bacteremia, and sepsis. Hepatic infection should be suspected when 
serum aminotransferase levels are elevated in the absence of other 
explanations. 
Hepatic infection in persons with bacillary angiomatosis may 
present as peliosis hepatis, or blood-filled cysts. Histologically, peliosis in 
patients with AIDS is characterized by an inflammatory myxoid stroma 
containing clumps of bacilli surrounding the blood-filled peliotic cysts. 
Diagnosis of Bartonella infection by polymerase chain reaction–based 
methods is being used more often.27   along with Warthin-Starry silver 
staining of infected tissue, chocolate agar culture 
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FUNGAL INFECTIONS: 
 
Cryptococcal, coccidioidal, and histoplasmal infections are usually 
seen in association with systemic disease.28,29  Liver involvement may be 
macro- or microscopic.  Candida rarely infects the liver, despite its high 
prevalence in mucocutaneous sites.  Hepatic Candida infections are 
confined to patients who are neutropenic, typically in response to 
systemic chemotherapy used to treat non-Hodgkin’s lymphoma.  Fungal 
infections especially histoplasma are associated with granulamatous 
hepatitis30,31  Tashjian LS, Abramson JS, et al., studied about the 
occurrence of granumotous hepatitis in AIDS patients.30  
PNEUMOCYSTIS CARINII INFECTION: 
Rare cases of Pneumocystis carinii or microsporidial infection in 
the liver have been reported32.  The presence of P carinii in extra- 
pulmonary sites typically is seen in patients who have had inhalation 
therapy with a drug such as pentamidine, which fails to protect sites 
outside the airways.   
HIV INFECTION PER SE AND HEPATOBILIARY 
ABNORMALITIES 
Typically, HIV is found within hepatic macrophages and 
occasionally sinusoidal endothelial cells.  Infection of macrophages is not 
surprising, given the propensity of the virus to infect the cell type in other 
organs16.  Nonetheless, infection of hepatic macrophages by HIV suggests 
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that the liver may be a large reservoir of virus.  Additionally, HIV 
infection of Kupffer’s cells could result in impaired cell function, leading 
to the increased incidence of enteric bacteremias in, this population.  
Despite the demonstration of HIV in liver, there is no discrete clinical 
syndrome of liver disease that has been ascribed to HIV alone. 
Liver abnormalities commonly associated with drugs used in the 
treatment of HIV and its complications. 
Predominantly Hepatocellular 
Disease 
Predominantly Cholestatic Disease 
Clarithromycin            Delaviridine 
Didanosine (ddl)         Efavirenz 
Dideoxycytidine (ddc)                    
Indinavir                     Isoniazid         
Ketoconazole              Nelfinavir       
Nevirapine                  Pentamidine    
Ritonavir                     Saquinavir      
Stavudine (d4T)    
Trimethoprimsulfamethoxazole       
Zidovudine 
Rifampin                                                  
Ketoconazole 
Trimethoprim- Sulfamethoxazole  
Dapsone 
 
 
Drug Reactions Caused by drugs used in the management of HIV:   
 
Drug Reactions are the commonest cause of Jaundice in AIDS33 -  
Potentially hepatotoxic drugs frequently used in the management of HIV- 
positive patients are summarized in the previous Table. Liver 
abnormalities associated with most of these drugs are typically indicative 
of hepatocellular injury, although certain drugs are associated with a 
predominantly “cholestatic pattern of liver injury.  The use of highly 
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active antiretroviral therapy (HAART) against HIV has become the 
standard of care.   
Hepatotoxicity has been noted with all of the protease inhibitors as 
well as many of the nucleoside and nonnucleoside analog drugs.  A recent 
study compared the incidence of hepatotoxicity in patients receiving 
several different regimens with and without protease inhibitors and found 
that ritonavir was associated with a higher incidence of hepatotoxicity 
when compared with indinavir, nelfinavir, saquinavir, and nucleoside 
analog regimens34. 
 Fortgang et al., described hepatomegaly and steatosis with enzyme 
elevation in AIDS patients receiving Antiretroviral therapy and he further 
stated that more than 10 fold elevation of liverenzymes with symptoms of 
liverdysfunction are the indications to stop ART.34  Hepatic steatosis is 
another pattern of injury noted as a complication of HIV medications.34  
Hepatic steatosis in the setting of lactic acidosis has been described for 
zidovudine, didanosine, and now stavudine.  Lactic acidosis can be 
diagnosed clinically with the following features, abdominal pain, 
distension, vomiting, fatiguiability, weight loss.  Lactic acid level is <2IU 
normally.  More than 5IU is an indication to stop treatment.  
Some patients have developed progressive, fatal hepatic steatosis.  
Typically, the syndrome has occurred in patients who appear to be 
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relatively well and has been ascribed to mitochondrial injury.35  Two 
other frequently noted problems are sulfa allergy with associated liver 
toxicity and hyperbilirubinemia in the setting of indinavir.  This is 
primarily an elevation in unconjugated bilirubin and is not related to liver 
injury.36 
Immune Reconstitution syndrome   
 It is a paradoxical reaction characterized by Overt manifestation of 
sub clinical infection after 3-6 months of ART.  It is due to improvement 
in CD4 levels after ART and is a good sign of recovery.  Any 
opportunistic infections may manifest, the common ones being 
tuberculosis, herpeszoster etc., ART should not be stopped and should be 
continued along with the treatment of the underlying infections.   
NEOPLASMS: 
Non-Hodgkin’s lymphoma:   
 Non-Hodgkin’s lymphoma (now referred to as either large cell 
lymphoma or Burkitt’s lymphoma, depending on the histologic findings) 
typically presents in extranodal sites, and occurs at all stages of HIV 
infection with equal frequency.  The liver is among the more common 
extranodal sites; there may be focal hepatic lesions associated with pain, 
weight loss, night sweats, and a progressive rise in both alkaline 
phosphatase and transaminase levels.37   
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 The lesion is typically identified by noninvasive imaging, and 
diagnosis can be established by an experienced pathologist using fine-
needle aspiration and cytologic or conventional liver biopsy. The 
prognosis of non-Hodgkin’s lymphoma is largely correlated with the 
stage of HIV infection and extent of immuno compromise.  Although not 
strictly an AIDS- defining diagnosis, advanced-stage Hodgkin’s 
lymphoma, often with visceral involvement, is also seen with increased 
prevalence in all risk groups. 
Kaposi’s sarcoma:   
 Kaposi’s sarcoma is a neoplasm that is largely confined to skin and 
mucous membrances but can involve the liver.  Recent evidence has 
revealed that greater than 85% of tumors are associated with a virus that 
has been named Kaposi’s sarcoma-associated herpes virus (KSHV) or 
human herpesvirus 8 (HHV-8).  Hepatic lesions are usually 
asymptomatic; however, there have been reports of bleeding from lesions 
following liver biopsy. Chemotheraphy or Radiotheraphy are the 
treatment options.       
Biliary tract diseases :           
AIDS Cholangiopathy :  
 It is a biliary syndrome diagnosed by clinical features, dramatic 
elevation of alkaline phosphatase, evidence of cryptospora in stools, 
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characteristic findings in ultrasonogram (USG), Computed Tomogram 
(CT) scan and Endoscopic Retrograde cholangio pancreatography 
(ERCP).38 It is diagnosed by John cello in 1989.  Amitsharma and Lalit 
Dugal et al., found out that estimated incidence of AIDS cholangiopathy 
was 45% in their study (including Asymptomatic).38   It is common when 
CD4 count is <100. 
 HIV per se won't cause AIDS Cholangiopathy. Opportunistic 
infections contribute for 50-81% of the cases. Cryptospora, CMV, 
Microspora are the common organisms, others include Cyclospora, 
Isospora, MAC, salmonella, enterobacter, candida etc.39 Pathogenesis is 
not clear, may be due to cytopathic effect over biliary epithelium, 
periductal inflammation and cholangiocyte apoptosis. AIDS 
Cholangiopathy is identified as following four entities.40                                                       
1. Papillary stenosis with common bile duct dilatation (>8 mm)                                     
2. Sclerosing cholangitis (focal stricture and dilatation of intrahepatic 
with or without extrahepatic ducts)  
3. Papillary stenosis and Sclerosing cholangitis                                                               
4. Long extrahepatic stricture (1-2cms long)  
Clinical features of AIDS Cholangiopathy include fever, right 
upper quadrant pain, asymptomatic also. Jaundice is extremely unusual.41 
Marked elevation of alkaline phosphatase and normal or mild elevation of 
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ALP and AST are observed. ALP is a good prognostic indicator.42 It is 
noted that Ultrasound has - 97% sensitivity & 100% specificity. Findings 
include common bile duct dilatation (>8 mm), terminal stenosis (distal 
Common Bile Duct (CBD) tapering 2-4mms),  dilatation of intrahepatic 
& extrahepatic ducts and focal strictures, distention and wall thickening 
in gallbladder.  
CT scan has highest diagnostic yield for dilatation. ERCP is gold 
standard. Cryptospora in stools, IgM Ab for CMV are the other useful 
tests. Anti Microbial Therapy has no effect over biliary tract.39 Anti Retro 
viral Therapy is the treatment of choice. Surgical intervention like 
Sphincterotomy, stenting, cholecystectomy can be done in the presence of 
pain and obstruction.   
Acalculous cholecystitis :  
 It is commonly caused by cytomegalovirus in HIV patients.43 
Patients present with severe abdominal pain with or without peritonitis. 
Wind P, Chevallier JM, et al., observed that cytomegalovirus is a 
common cause of Acalculous Cholecystitis.44  It is surgical emergency. 
Cholecystectomy is the treatment of choice.   
Non-Hodgkin's lymphoma, Kaposi's Sarcoma: 
   Rare cases of Non-Hodgkin's lymphoma or Kaposi's sarcoma have 
been reported in the biliary tree, reflecting the aggressive nature and 
unusual presentations of these neoplasms in this setting.                                                       
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                     Materials and Methods 
 
 
Setting             :     This study was carried out at  
                                                      Government Rajaji   Hospital,  
Madurai 
 
Collaborating Departments    :     Department of Medicine, 
      Dept of Sexually Transmitted Diseases,  
      ART Center,  
Dept of Medical Gastro Enterology 
 
Study Design                          :     Prospective study 
 
Period of study                       :     January 2005 - September 2006 
 
 
Sample size and selection of study subjects :  
 
The study was conducted in HIV positive patients, who were 
attending the ART Center, GRH, Madurai.    
Among the patients attending ART Center, 100 patients who 
satisfied the inclusion criteria were included in the study and further 
evaluated. 
 
Inclusion criteria: 
 
1. Adult male and Non-pregnant female  who are HIV positives. 
2. Patients who are eligible for Anti Retro Viral Therapy                         
Based on CD4 counts and WHO clinical staging.  
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Exclusion criteria:  
 
1. Children 
2. Pregnancy  
3. Patients on Hepatotoxic drugs (Anti TB, Anti 
Epilepsy drugs, alcohol etc., 
Ethical issues :    
 
The study group thus identified by the above criteria (Inclusion & 
Exclusion) were first briefed about the nature of the study .Willing 
participants were taken up, after getting a written informed consent from 
them.  
Materials  : 
 
100 cases, who satisfied the  inclusion & exclusion criteria  above 
were taken up for the study. 
Conflict of interest :   
 
There was no conflict of interest. 
 
Financial Support 
 
 No 
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Methodology 
 
 
Selected   Socio demographic, clinical and laboratory Data were 
elicited from the patients and recorded in a proforma. 
 
1. Socio Demographic Data : 
 
Economic and Educational Status and Demography 
                                     
                                  Age 
 
                                  Sex 
2. Clinical Data : 
          
                                  clinical examination 
 
3. Laboratory Data : 
 
                               TC     Urine   Albumin 
 
                               DC                     Sugar 
  
                               Hb%                      Deposits 
 
                               ESR 
CD4 count 
 
Blood sugar 
 
           Urea 
 
Serum creatinine 
 
Serum electrolytes 
 
LFT : Serum bilirubin –  Total 
                                        Conjugated 
                                        Unconjugated 
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          Serum Glutamate Oxalo Acetate Transaminase (SGOT) 
          Serum Glutamate Pyruvate Transaminase (SGPT) 
          Alkaline Phosphatase (ALP) 
          Serum proteins – Total 
                                      Albumin 
                                      Globulin 
 
          Hepatatis B Surface Antigen  (HBsAg) 
 
          Anti HCV  
          
UltraSonoGram -  Abdomen 
 
CT Scan - Abdomen (if required for further confirmation) 
 
CD4 Count : 
   
The standard method for enumerating CD4 T cells uses a flow 
cytometer. A computer calculates the number of CD4 T cells by 
analyzing the size of the cell and which of the antibodies , it has been 
tagged with. The over all process is called Fluorescence Activated Cell 
Sorting (FACS) 
Statistical Analysis :  
 
Data was entered in Microsoft excel spread sheet and analyzed. 
Statistically using standard statistical software. 
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AGE AND SEX DISTRIBUTION 
 
 
 
 
Age < 20 21- 30 31- 40 41- 50 >50 
Males 2 5 44 9 4 
Females 0 18 17 1 0 
 
 
Of the 100 patients, 64 were males and 36 were females. The age 
ranged from 18 to 61 years in males with mean age of 35.58 years. 
Among the females, the age range was 24 to 43 years with average of 
31.69 years. 
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Socio Demographic Data 
 
 
Educational status 
 
 
Level of education Total No. of patients Males Females 
Illiterate  36 18 18 
Primary school 46 36 10 
High school 14 8 6 
Degree/ Diploma 4 2 2 
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Occupational Status  
 
 
 
S. No Occupation Numbers 
1 Cooly 34 
2 Driver 11 
3 Housewife 29 
4 Clerk 4 
5 Farmer 8 
6 Others 14 
 Total 100 
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Marital status: 
 
Marital status Male Female Total 
Married 48 36 84 
Unmarried 16 0 16 
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Investigations  
 
S.no Investigations Range Mean 
1 Blood TC 4800 - 7400 6200 
2 Blood Hb 7.6 – 10.8 9.2 
3 Blood Sugar 60 - 312 89.6 
4 Blood Urea 18 – 42 24.1 
5 Serum Creatinine 0.7 – 1.4 0.93 
6 CD4 Count 17 - 306 97.6 
7 Pre ART 
Sr.Bilirubin 
0.6 - 3 0.994 
8 Pre ART 
Sr.Protien 
4.6 – 6.4 5.796 
9 Pre ART SGOT 17 - 134 32.5 
10 Pre ART SGPT 11 - 142 33.72 
11 Pre ART ALP 22 - 603 119.94 
12 Post ART 
Sr.Bilirubin 
0.6 – 1.1 0.816 
13 Post ART SGOT 18 - 66 32.4 
14 Post ART SGPT 17 - 117 39.14 
15 Post ART ALP 35 - 284 98.08 
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Incidence of hepatobiliary abnormalities in AIDS. 
 
 
Total incidence of hepatobiliary abnormalities is 15% in 
asymptomatic AIDS patients. Among this 15%, 2% had hepatic 
abnormalities, 8% had AIDS cholangioapathy.  4% had HBS Ag 
positivity and 1% had anti HCV positivity. 
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AGE, GENDER AND CD4 COUNT CORRELATION 
 
 
CD4 COUNTS 
<50 51- 100 101- 200 > 200 
 
 
Male Female Male Female Male Female Male Female 
<20 0 0 0 0 0 0 2 0 
21 - 30 3 3 0 5 2 6 0 4 
31 - 40 15 6 15 8 14 1 0 2 
41 - 50 2 1 0 0 5 0 2 0 
> 50 2 0 0 0 0 0 2 0 
Total 22 10 15 13 21 7 6 6 
 
Most of the patients (72%) were taking Zidovudine + Lamivudine 
+ Nevirapine Regimen.  
 
Others (28%) were on Stavudine + Lamivudine + Nevirapine 
Regimen. 
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CD4  COUNT CORRELATION WITH HEPATOBILIARY 
ABNORMALITIES 
 
 
 
CD4 count Hepatobiliary Abnormalities 
<50 1% Anti HCV Positivity  
50-100 6% AIDS Cholangiopathy  
4% HBs Ag Positivity 
100-150 2% AIDS Cholangiopathy 
2% Hepatic Abnormalities 
150-306 -- 
 
 
 CD4 count of the patients range from 17-306.  All the patients 
having hepatobiliary abnormalities had CD4<150.  1% AntiHCV 
Positivity had CD4<50.  6% AIDS Cholangiopathy  and 4% HBs Ag 
Positivity had CD4 between 50-100.  2% AIDS Cholangiopathy and 2% 
Hepatic Abnormalities had CD4 between 100-150.  So, CD4 count has an 
inverse relationship with hepatobiliary abnormalities.   
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HIV – HBV co infection 
 % of 
positivity 
Liver 
function 
tests  
Ultra-
Sonogram 
CD4 
Count  
HIV-HBV 
co 
infection 4% 
2% with 
<2 fold 
increase in 
SGOT/SGPT 
Normal <100 
HIV-HCV 
co 
infection 
1% Normal Normal <50 
 
 HBsAg Positivity was seen in 4 out of 100 HIV patients. Among 
these male : female ratio was 1:1 .All were asymptomatic . CD4 count 
was less than 100 in all 4 patients.  Out of 4 patients, < 2 fold elevation of  
Pre ART SGPT was noted in 2 patients. But normal Post ART SGPT was 
seen in those 2 patients.  Remaining 2 patients with normal Pre ART 
SGPT got <2fold elevation of Post ART SGPT. Sr. Bilirubin, Sr.Protein, 
ALP were normal in all 4 patients in Pre and Post ART. No Anti HCV 
positivity was noted in these 4 HbSAg positive patients. Ultrasonogram  
abdomen was normal in all these patients.  
HIV-HCV co infection 
Anti HCV positivity was noted in One male patient. He was 
asymptomatic . CD4 count was 46 cells. Pre ART LFT as well as Post 
ART LFT were within normal limits. HbSAg was negative. 
Ultrasonogram  abdomen was  also normal. 
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RESPONSE OF HEPATIC ABNORMALITIES TO  
ANTI RETROVIRAL THERAPY  
 
 
 
Among 100 patients, 2 patients had > 2 fold elevation of SGOT / 
SGPT  before starting ART and hepatomegaly in USG. Both of them 
had normal values after ART.  
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RESPONSE OF AIDS CHOLANGIOPATHY TO 
ANTIRETROVIRAL THERAPY 
 
 SGOT SGPT ALP 
 M S.D. ‘P’ value M S.D 
‘P’ 
value M S.D 
‘P’ 
value
Pre 
ART  
39 12.26 48 22.06 342.5 182.97 
Post 
ART  
28.5 5.78 0.011 33.25 9.3 0.035 188.25 87.05 0.035
 
 M  - Mean 
 S.D. - Standard Division  
 There is statistically significant difference between liver enzymes 
(SGOT/SGPT/ALP) in AIDS Cholangiopathy before and after ART. 
(According to WILCOXON SIGNED RANKS TEST, ‘P’ Value<0.05 
is significant). 
 
AIDS Cholangiopathy was noted in 8 % of cases. Male : Female 
ratio was 1:1 . 6 out of 8 patients had CD4 < 100. Remaining 2 had 100 – 
120. All patients were clinically asymptomatic. LFT showed that marked 
elevation of ALP and normal SGOT & SGPT. Ultrasonogram showed 
Sclerosing Cholangitis, Papillary Stenosis and Thickening of CBD with 
Biliary Sludge. 2 cases had hepatomegaly also. HBsAg and Anti HCV 
were negative in all cases. 
After HAART, ALP values come down, with the resolution of 
AIDS cholangiopathy.  
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ANTI RETROVIRAL THERAPY INDUCED SGOT / SGPT 
ELEVATION 
 
 
In 6 patients, 2-3 fold elevation of SGOT / SGPT after ART was 
noted due to  ART induced Liver enzyme elevation who had normal 
values before ART. 2 out of 6 patients had fatty liver in USG. 
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ALKALINE PHOSPHATASE  ELEVATION AFTER 
ANTIRETROVIRAL THERAPY  
 
 
 
 2% of Patients had 2 fold ALP elevation, after starting ART, may 
be due to immune reconstitution or ART induced Liver enzyme elevation.  
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Ultra sound findings 
 30% had hepatomegaly and fatty liver. 15 out of 30 had elevation 
of liver enzymes also.   
 8% had AIDS cholangiopathy with Sclerosing cholangitis, 
papillary stenosis and thickening of CBD with Biliary sludge.  
 2% had gallstones with elevated billirubin  
 Incidently 2% were found have pancreatitis. 
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DISCUSSION 
 
A study of Hepato – biliary abnormalities in 100 AIDS patients 
was done. In literature, it is stated that Hepatic disorders are due to Viral 
Hepatitis, Opportunistic infections, Tumors and Hepato toxic drugs10.  In 
our study , 64 males & 36 females were included. Age ranged from 18 to 
61 years, with most of them being illiterates and few had primary school 
level education.  Most of them were married and house wives, majority 
were coolies by occupation. 
Clinically all of them were asymptomatic. Their CD4 counts 
ranged from 17 to 306. Mean was 97.6.  72 % of patients were taking  
Zidovudine + Lamivudine + Nevirapine Regimen. Remaining 28 % were 
taking Stavudine + Lamivudine + Nevirapine Regimen.  All were on 
cotrimoxazole  for Opportunistic Infection (OI) prophylaxis. 
 
Hepatobiliary abnormalities in AIDS Patients 
 
Interpretation of Liver function tests :  
 
Serum Billirubin was almost normal for all patients except very 
few who had gall stones.  Serum albumin was normal for all. SGOT and 
SGPT were mildly elevated ( < 2 fold )  in  many patients.  Reynolds et 
al., described that hepatic abnormalities are commonly due to 
opportunistic infections like Myco TB, CMV, MAC etc and                
 50
upto 10% hepatic abnormalities were noted in their study.20  In our study 
2% of patients, who were asymptomatic  had 2–3 fold elevation of  
SGOT/ SGPT with mild hepatomegaly (no echo pattern changes or focal 
lesions), before starting ART. Both of them had normal values after ART.  
This finding is suggested that they might have had opportunistic 
infections like CMV, MAC etc. which responded very well due to 
immune restoration after ART.   
Amitsharma and Lalit Dugal et al., found out that estimated 
incidence of AIDS cholangiopathy was 45% in their study (including 
Asymptomatics).38  In our study 8 % of patients had significant elevation 
(>4 fold ) of  ALP  before starting ART,  with ultrasound and CT 
confirming AIDS Cholangiopathy. All were asymptomatic. All of them 
had normal values after ART. 
AIDS Cholangiopathy :  
It is a biliary syndrome diagnosed by clinical, dramatic elevation of 
alkaline phosphatase, evidence of cryptospora in stools, characteristic 
findings in ultrasound, CT scan and ERCP. Estimated incidence is 45% 
including asymptomatics38.  It is common when CD4 count is <100. HIV 
per se won't cause cholangiopathy.     
Opportunistic infections contribute for 50-81% of AIDS 
Cholangiopathy. Cryptospora, CMV, Microspora are the common 
organisms. Others include Cyclospora, Isospora, MAC, salmonella, 
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enterobacter, candida etc. Jaundice is extremely unusual. Marked 
elevation of alkaline phosphatase and normal or mild elevation of ALP 
and AST are observed. ALP is a good prognostic indicator. In our study, 
8 % of cases who were asymptomatic had elevation of ALP ( > 4 folds ) 
with characteristic  Ultrasound findings suggestive of cholangiopathy. 6% 
of patients had CD4 < 100. Remaining 2%  had 100 – 120. In literature it 
is stated that, Ultrasound has 97% sensitivity & 100% specificity. 
Findings include common bile duct dilatation (>8 mm), terminal stenosis 
(distal CBD tapering   2-4mms),  dilatation of intrahepatic & extrahepatic 
ducts and focal strictures, distention and wall thickening in gallbladder40.  
CT scan has highest diagnostic yield for dilatation. ERCP is the 
gold standard. In our study, USG abdomen had 100 % sensitivity & 100% 
specificity. We noted Sclerosing Cholangitis, Papillary Stenosis and 
Thickening of CBD with Biliary Sludge. Anti Microbial Therapy has no 
effect over biliary tract. Anti Retro viral Therapy is the treatment of 
choice. Our patients responded very well to ART as evidenced by 
normalization of ALP and disappearance of the USG / CT findings within 
3-5 months of ART. 
Ultra Sonogram Abdomen : 
30 % of cases had either fatty liver or hepatomegaly with out focal 
lesion.  This is due to either ART  drugs  toxicity ( hepatic steatosis) or 
opportunistic infection like MAC , CMV etc. Gramse et al. observed that 
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10-12% of AIDS Patients had USG evidence of Sclerosing Cholangitis , 
Papillary Stenosis in their study.40 In our study 8% of cases had 
Sclerosing Cholangitis , Papillary Stenosis and Thickening of CBD with 
Biliary Sludge  suggestive of AIDS Cholangiopathy. 2 % of cases had 
gall stones.  Incidentally, 2% of cases were found to have features 
suggestive of pancreatitis. 
CD4 Correlation with hepatobiliary abnormalities 
 CD4 has an inverse relationship with hepatobiliary abnormalities, 
since opportunistic infections are commonly observed whenever the CD4 
count decreases.  
 Forbes et al., observed that AIDS Cholangiopathy is common when 
CD4 count is <10041.  In this study 6% of AIDS Cholangiopathy had CD4 
<100 and 2% of the same had CD4 100-120.  2% of hepatic abnormalities 
(Elevation of SGOT / SGPT elevation with hepatomecaly) had CD4 
between 100-120. 4% of HBsAg positivity had CD4 <100 and 1% of 
HCV positivity had CD4 <50. 
HBV and HCV Co-infection in HIV Patients 
HIV – HBV Co infection:  
In literature, it is stated that Both viruses have an increased 
prevalence in persons with multiple sexual partners and in injection drug 
users.12  Markers of prior or active HBV infection are present in more 
than 80% of patients with HIV infection, approximately 10% of whom 
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are HBsAg positive, as described by Hollander et al.13.  But in this study , 
we have noted , only 4 % were HBsAg positive with the possible mode of 
transmission being sexual route.  Reason being  injection drug users are 
less common in our set up. All were asymptomatic with no signs of liver 
cell failure. CD4 count was less than 100 in all 4 patients. Liver function 
tests including serum protein were within normal limits except mild 
elevation (< 2 fold) of SGPT.    
Ultra Sonogram Abdomen was also normal. Anti HCV was 
negative. Co infected patients are at greater risk of developing chronic 
HBV infection like Chronic active hepatitis and Cirrhosis. Patients with 
evidence of actively replicating virus and liver disease should be 
considered for treatment. Lamivudine administered at 100 mg/day is 
sufficient to control HBV.  In our study, we did not observe any active 
liver diseases. Our patients were on HAART due to AIDS. They were 
getting Lamivudine at a dose of 150 mg Twice daily.  
HIV – HCV Co Infection:  
 
Berenguer and wright et al., observed that rates of HCV 
seropositivity ranging from 4% to 100% in their study, depending on the 
transmission category, with higher rates among injection drug users and 
recipients of blood transfusions than among homosexual men and 
heterosexual contacts.15 In our study, only  1%  was noted, with the 
possible mode of transmission being sexual route.  Injection drug users 
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are less common in our set up. All were asymptomatic with no signs of 
liver cell failure. CD4 count was 46 cells. Liver function tests were within 
normal limits.  UltraSonogram Abdomen was also normal. HBsAg was 
negative. The clinical course of HCV infection in HIV patients is often 
more aggressive. Multiple studies have demonstrated an increased rate of 
fibrosis and prevalence of cirrhosis.  
Chronic hepatitis C is a growing cause of morbidity and mortality 
in patients who are HIV positive. Indeed, several studies have shown that 
HIV/HCV–co infected patients have more severe liver injury and a worse 
prognosis than do patients with HCV infection alone.15 Our patient didnot 
have active liver disease. But, he was on HAART due to AIDS.  
Antroviral  therapy induced hepatobiliary abnormalities 
Fortgang et al., described hepatomegaly and steatosis with enzyme 
elevation in AIDS patients receiving Antiretroviral therapy and he further 
stated that more than 10 fold elevation of liver enzymes with symptoms 
of liver dysfunction are the indications to stop ART.34   In this study, 8% 
of patients had Liver enzymes elevation–6% with SGOT/SGPT elevation 
and 2% with ALP elevation.  Out of Total 8%, in 6 % of patients, 2-3fold 
elevation of SGOT / SGPT after ART was noted who had normal values 
before ART. They were taking Nevirapine, Lamivudine, Zidovudine or 
Stavudine, and co-trimoxazole for OI Prophylaxis. This is due to either 
drug toxicity or immune reconstitution. They are continuing drugs, but 
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they are under observation. Liver abnormalities associated with most of 
these drugs are typically indicative of hepatocellular injury, although 
certain drugs are associated with a predominantly cholestatic pattern of 
liver injury.  
ALP was mildly elevated (<2 fold) in many patients. Out of Total 
8% of ART induced enzyme elevation, in 2 % of patients, significant 
elevation of ALP ( 2-3 fold ) after ART was noted who had normal values 
before ART. This is mainly due to immune reconstitution or drug 
toxicity.  
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LIMITATIONS 
 
 
 
1. Liver biopsy was not attempted due to ethical reasons. 
 
2. HIV viral load could not be estimated  due to constraints. 
 
3. Specific diagnostic tests for  individual opportunistic organisms, 
such as Motion culture for cryptospora, CMV IgM ab testing,             
ERCP for cholangiopathy, were not done. 
 
4. HBeAg, HBV DNA,HCV RNA were not done. 
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CONCLUSIONS 
 
1. The incidence of definite hepatobiliary abnormalities in AIDS 
supported by both USG and biochemical findings was 15% in 
asymptomatic patients, but USG alone suggested 30% incidence of 
the same. Among the 15% of patients with hepato- biliary 
abnormalities, 2% had hepatic involvement (SGOT/SGPT 
elevation with hepatomagaly), 8% had biliary (AIDS- 
Cholangiopathy) 4% had HBs Ag Positivity and 1% with anti HCV 
positivity.  
 
2. It was observed that CD4 count and hepatobiliary abnormalities 
had inverse relationship.  Of 8% patients with HIV cholangiopathy, 
6% had CD4 < 100 and 2% had CD4 100-120. 2% of patients with 
hepatic abnormalities (SGOT/SGPT elevation with hepatomegaly) 
had CD4 between 100-120. All the 4% pts with hepatitis B had 
CD4 < 100 and 1% hepatitis C had < 50. 
 
3. The incidence of HIV – HBV coinfection was 4% and HIV–HCV  
coinfection was 1%, all patients were asymptomatic with no 
evidence of active liver disease. 
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4. 2% of hepatic abnormalities (SGOT/SGPT elevation with 
hepatomegaly) and 8% of AIDS cholangiopathy responded very 
well to 3 to 5 months of ART. 
 
5. Incidence of significant POST ART hepatobiliary abnormalities 
was 8% with 6% having 2-3 fold SGOT, SGPT elevation and 2% 
having 2 fold ALP elevation, which warranted only a close follow 
up but not ART withdrawal. 
 
 59
SUMMARY 
 
 
 
 The present study was undertaken with an aim to find out hepato- 
biliary abnormalities in AIDS patients, with CD4 count correlation, HBV, 
HCV coinfection with HIV and the response of hepato-biliary 
abnormalities to ART including ART induced hepato-biliary 
abnormalities.  100 AIDS Patients after satisfying inclusion and exclusion 
criteria were included in the study and they were evaluated regarding 
hepato- biliary abnormalities.   
In our study, 64 males & 36 females were included. Age ranged 
from 18 to 61 years, with most of them being illiterates and few had 
primary school level education.  Most of them were married and house 
wives, majority were coolies by occupation.  Clinically all of them were 
asymptomatic. Their CD4 counts ranged from 17 to 306. Mean was 97.6.  
72 % of  patients were taking  Zidovudine + Lamivudine + Nevirapine 
Regimen. Remaining 28 % were taking Stavudine + Lamivudine + 
Nevirapine Regimen.   
The incidence of definite hepatobiliary abnormalities in AIDS 
supported by both USG and biochemical findings was 15% in 
asymptomatic patients, but USG alone suggested 30% incidence of the 
same. Among the 15% of patients with hepato biliary abnormalities, 2% 
had hepatic involvement (SGOT/SGPT elevation with hepatomagaly), 
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8% had biliary(AIDS Cholangiopathy) 4% had HBs Ag Positivity and 1% 
with anti HCV positivity.  It was observed that CD4 count and 
hepatobiliary abnormalities had inverse relationship.  Of 8% patients with 
HIV cholangiopathy, 6% had CD4 < 100 and 2% had CD4 100-120.    2% 
of patients with hepatic abnormalities (SGOT/SGPT elevation with 
hepatomegaly) had CD4 between 100-120. All the 4% pts with hepatitisB 
had CD4 < 100 and 1% hepatitis C had < 50. 
The incidence of HIV-HBV co-infection was 4% and HIV–HCV 
co-infection was 1%, with the possible mode of transmission being 
heterosexual route, all patients were asymptomatic with no evidence of 
active liver disease.  2% of hepatic abnormalities (SGOT/SGPT elevation 
with hepatomegaly) and 8% of AIDS cholangiopathy responded very 
well to  3 to 5 months of ART.  Incidence of significant POST ART 
hepatobiliary abnormalities was 8% with 6% having 2-3 fold SGOT, 
SGPT elevation and 2% having 2 fold ALP elevation, which warranted 
only a close follow up but not ART withdrawal. 
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APPENDIX - 2 
 
PROFORMA 
 
Name :                                                    Age :                  Sex :      Wt : 
 
Address :                                                 Education:                           
Occupation : 
 
 
Complaints :  
 
H/o Present illness : 
 
H/o jaundice / high coloured urine / pale stools / itching / abdominal pain 
H/o nausea / vomiting / fever  
H/o haematemesis / malena / other bleeding manifestations 
H/o distension of abdomen / swelling of legs / dyspnoea 
H/o oral lesions / dysphagia / diarrhoea 
H/o skin rashes 
 
H/o Past illness : 
 
H/o jaundice / blood transfusion 
H/o diagnosis of HIV :       when :                             where :                               
Reason for testing : 
        Mode of transmission : 
H/o ART : Started on :                                               Regimen :                          
Adherence : 
H/o TB / ATT 
H/o epilepsy / Anti convulsants 
H/o any other chronic drug intake 
H/o DM / HT 
 
Personal History : 
 
Smoker / Alcoholic :                                                  duration :                           
stopped / not 
Drug abuse : 
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Family History : 
 
H/o HIV  positivity in spouse / children 
H/o ART : spouse / children 
H/o jaundice in family members 
General Examination : 
 
Built / Nourishment / Conciousness / Orientation 
Anaemia /Jaundice / Cyanosis / Clubbing 
Pedal edema / Generalized lymphadenopathy 
Spider naevi / Palmar erythema 
Gynaecomatia / Testicular atrophy 
Temp :                  PR :                    BP :                    RR : 
Oral cavity : OC / OHL / Aphthous ulcers 
                    Gingivitis / Pharngitis / Herpes labialis 
                    Hyper pigmentation of tongue / buccal mucosa 
Skin           : IBA / PPE / Seb.derm / Scabies 
                    Fungal infection / Herpes zoster / Impetigo 
CVS          : S1,S2+         Murmur : 
RS            : NVBS +         Added sounds : 
 
Abdomen : soft / moves with respiration / tenderness 
                   distended / not 
                   dialated veins / not 
                   free fluid / not 
Organomegaly :                                    Liver :                           Spleen : 
Size : 
Extension : 
Margin : 
Moves with respiration : 
Surface : 
Consistency : 
Tenderness : 
Bruie : 
External genitalia : Any genital lesion / Inguinal nodes 
 
Investigations :  
Blood  TC :                  DC :                          Hb : 
Urine Alb   :               Sug :                        Dep : 
Blood Sugar :                Urea :                 S.Creatinine : 
Blood VDRL :                ELISA : 
CD4 count :                     CD8 :                           Ratio : 
                                                                      Pre ART                         Post  ART 
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LFT : 
 
S. bilirubin -  Total 
                      Direct 
                      Indirect 
SGOT 
SGPT 
ALP 
Serum Protein 
HbSAg 
HCV 
USG Abdomen :  Liver : 
Span 
Echo pattern 
Focal lesion 
IHBR dilatation 
Portal vein 
 
GB : 
wall thickening 
                                       focal lesion 
                                       peri GB fluid 
                                       calculus 
                                       CBD 
 
Pancreas : 
                                       size & echo pattern 
                                        focal lesion    
                                        calcification 
                                        pancreatic duct 
 
Spleen :  
                                       size & echo pattern  
                                       focal lesion                                                  
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APPENDIX – 3 
 
ABBREVIATIONS 
 
 
AIDS    - Acquired Immuno Deficiency Syndrome 
 
ART / ARV   - Anti retroviral therapy  
 
ALP   - Alkaline phosphatase  
 
CBD    - Common Bile Duct  
 
CMV    - Cyto megalo Virus 
 
ERCP   - Endoscopic Retrograde cholangio pancreatography  
 
HAART   - Highly active Anti retroviral therapy 
 
HIV    - Human Immuno Deficiency Virus 
 
HCV    - Hepatitis C Virus  
 
HBV   - Hepatitis B Virus 
 
Myco TB  - Myco Bacterium Tuberculosis 
 
MAC    - Myco Bacterium Avium Intracellulare   
 
NRTI    - Nucleoside reverse transcriptase inhibitors 
 
NNRTIS  - Non Nucleoside reverse transcriptase inhibitors 
 
OI   - Opportunistic infections 
 
PIS   - Protease inhibitors  
 
STD    - Sexually transmitted diseases 
 
SGOT   - Serum Glutamate Oxaloacetate Transaminase 
 
SGPT   - Serum Glutamate Pyruvate Transaminase 
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RESPONSE OF HEPATIC ABNORMALITIES TO 
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RESPONSE OF AIDS CHOLANGIOPATHY TO ANTI 
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